These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 9690721)

  • 1. Acid-inhibitory effects of omeprazole and lansoprazole in Helicobacter pylori-negative healthy subjects.
    Geus WP; Mulder PG; Nicolai JJ; Van den Boomgaard DM; Lamers CB
    Aliment Pharmacol Ther; 1998 Apr; 12(4):329-35. PubMed ID: 9690721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-response relationship of lansoprazole to gastric acid antisecretory effects.
    Blum RA; Hunt RH; Kidd SL; Shi H; Jennings DE; Greski-Rose PA
    Aliment Pharmacol Ther; 1998 Apr; 12(4):321-7. PubMed ID: 9690720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole.
    Katz PO; Hatlebakk JG; Castell DO
    Aliment Pharmacol Ther; 2000 Jun; 14(6):709-14. PubMed ID: 10848653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects.
    Timmer W; Ripke H; Kleist P; Ehrlich A; Wieckhorst G; Lücker PW; Fuder H
    Methods Find Exp Clin Pharmacol; 1995 Sep; 17(7):489-95. PubMed ID: 8577212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of omeprazole and lansoprazole on 24-hour intragastric pH in Helicobacter pylori-positive volunteers.
    Verdú EF; Fraser R; Armstrong D; Blum AL
    Scand J Gastroenterol; 1994 Dec; 29(12):1065-9. PubMed ID: 7886393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
    Shimatani T; Inoue M; Kuroiwa T; Xu J; Mieno H; Nakamura M; Tazuma S
    Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of Helicobacter pylori eradication on intragastric pH during dosing with lansoprazole or ranitidine.
    van Herwaarden MA; Samsom M; van Nispen CH; Mulder PG; Smout AJ
    Aliment Pharmacol Ther; 1999 Jun; 13(6):731-40. PubMed ID: 10383501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo.
    Williams MP; Usselmann B; Chilton A; Sercombe J; Nwokolo CU; Pounder RE
    Aliment Pharmacol Ther; 2003 Mar; 17(6):775-83. PubMed ID: 12641499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the effect of lansoprazole in suppressing acid secretion using 24-hour intragastric pH monitoring.
    Takeda H; Hokari K; Asaka M
    J Clin Gastroenterol; 1995; 20 Suppl 1():S7-9. PubMed ID: 7673616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion.
    Blum RA; Shi H; Karol MD; Greski-Rose PA; Hunt RH
    Clin Ther; 1997; 19(5):1013-23. PubMed ID: 9385488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
    Saitoh T; Fukushima Y; Otsuka H; Hirakawa J; Mori H; Asano T; Ishikawa T; Katsube T; Ogawa K; Ohkawa S
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1811-7. PubMed ID: 12269976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of oral doses of lansoprazole and omeprazole on gastric pH.
    Tolman KG; Sanders SW; Buchi KN; Karol MD; Jennings DE; Ringham GL
    J Clin Gastroenterol; 1997 Mar; 24(2):65-70. PubMed ID: 9077718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-dependent eradication of Helicobacter pylori with dual therapy.
    Treiber G; Ammon S; Klotz U
    Aliment Pharmacol Ther; 1997 Aug; 11(4):711-8. PubMed ID: 9305480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acid suppression in healthy subjects following lansoprazole or pantoprazole.
    Huang JQ; Goldwater DR; Thomson AB; Appelman SA; Sridhar S; James CF; Chiu YL; Pilmer BL; Keith RG; Hunt RH
    Aliment Pharmacol Ther; 2002 Mar; 16(3):425-33. PubMed ID: 11876695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal.
    Hatlebakk JG; Katz PO; Camacho-Lobato L; Castell DO
    Aliment Pharmacol Ther; 2000 Oct; 14(10):1267-72. PubMed ID: 11012470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects.
    Bruley des Varannes S; Gharib H; Bicheler V; Bost R; Bonaz B; Stanescu L; Delchier JC; Bonnot-Marlier S
    Aliment Pharmacol Ther; 2004 Oct; 20(8):899-907. PubMed ID: 15479362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppressive action of lansoprazole on gastric acidity and its clinical effect in patients with gastric ulcers: comparison with famotidine.
    Sakaguchi M; Ashida K; Umegaki E; Miyoshi H; Katsu K
    J Clin Gastroenterol; 1995; 20 Suppl 2():S27-31. PubMed ID: 7594334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
    Giral A; Celikel CA; Ozdogan O; Tözün N; Ulusoy NB; Kalayci C
    J Gastroenterol Hepatol; 2005 Dec; 20(12):1886-91. PubMed ID: 16336449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of 7-day therapy with different doses of the proton pump inhibitor lansoprazole on the intragastric pH in healthy human subjects.
    Harder H; Teyssen S; Stephan F; Pfützer R; Kiel G; Fuchs W; Singer MV
    Scand J Gastroenterol; 1999 Jun; 34(6):551-61. PubMed ID: 10440603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40 mg during repeated oral administration in Helicobacter pylori-negative subjects.
    Geus WP; Mathôt RA; Mulder PG; Lamers CB
    Aliment Pharmacol Ther; 2000 Aug; 14(8):1057-64. PubMed ID: 10930900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.